Jaguar Health is proud to be celebrating National Service Dog Month “September is National Service Dog Month. Service dogs are incredible working animals who enable people to live more independently and enjoy a better quality of life. In some cases, service dogs can be the difference between life and death,” said Lisa Conte, Jaguar’s founder, president, and CEO. “These qualities align with Jaguar’s mission of providing supportive care to people and dogs suffering from complex disease states like cancer.” Canalevia-CA1, Jaguar’s U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is available on Chewy and from veterinarians across the U.S. By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based product sustainably harvested from the Croton lechleri tree.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health announces patent issued in Jordan for SBS treatment
- Jaguar Health’s Napo Pharmaceuticals issues Hong Kong patent for SBS treatment
- Jaguar Health reports Q2 EPS ($4.04) vs. ($41.35) last year
- Jaguar Health to explore approval pathway for crofelemer based on Phase 3 result
- Jaguar Health announces results of investigator-initiated studies of crofelemer